Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Choi, Eun Sun ^a   Nam, Jeong Seok ^b   Jung, Ji Youn ^c   Cho, Nam Pyo ^d   Cho, Sung Dae ^d  

^a Korea Centers for Disease Control and Prevention   (South Korea)

^b Gachon University   (South Korea)

^c Kongju National University   (South Korea)

^d Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CASPASE 8; MITHRAMYCIN; MITHRAMYCIN A; PEPTIDE HYDROLASE; PROTEIN BID; SP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MITOCHONDRIA; PEPTIDE HYDROLASES; PLICAMYCIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 84933686722     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07162     Document Type: Article

References (41)

1. Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2, 740-9 (2002).
2. Frank, D. A. Targeting transcription factors for cancer therapy. IDrugs 12, 29-33 (2009).
3. Chae, J. I., Lee, R., Cho, J., Hong, J. & Shim, J. H. Specificity protein 1 is a novel target of 2, 4-bis (p-hydroxyphenyl)-2-butenal in the suppression of human oral squamous cell carcinoma cell growth. J Biomed Sci 21, 4 (2014).
4. Lee, H. E. et al. Inhibition of specificity protein 1 by dibenzylideneacetone, a curcumin analogue, induces apoptosis in mucoepidermoid carcinomas and tumor xenografts through Bim and truncated Bid. Oral Oncol 50, 189-95 (2014).
5. Olofsson, B. A., Kelly, C. M., Kim, J., Hornsby, S. M. & Azizkhan-Clifford, J. Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia-mutated kinase. Mol Cancer Res 5, 1319-30 (2007).
6. Safe, S. & Abdelrahim, M. Sp transcription factor family and its role in cancer. Eur J Cancer 41, 2438-48 (2005).
7. Hsu, T. I. et al. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol Pharmacol 82, 1115-28 (2012).
8. Brown, K. C. et al. Nicotine induces the up-regulation of the alpha7-nicotinic receptor (alpha7-nAChR) in human squamous cell lung cancer cells via the Sp1/ GATA protein pathway. J Biol Chem 288, 33049-59 (2013).
9. Barcelo, F. et al. DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49, 10543-52 (2010).
10. Kennedy, B. J. & Torkelson, J. L. Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 24, 327-8 (1995).
11. Dutcher, J. P., Coletti, D., Paietta, E. & Wiernik, P. H. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 21, 375-80 (1997).
12. Miura, A. et al. Regulatory mechanism of PAC1 gene expression via Sp1 by nerve growth factor in PC12 cells. FEBS Lett 586, 1731-5 (2012).
13. Reamon-Buettner, S. M. & Borlak, J. Epigenetic silencing of cell adhesion molecule1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer Res 68, 7587-96 (2008).
14. Lee, K. A., Chae, J. I. & Shim, J. H. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci 19, 60 (2012).
15. Seznec, J., Silkenstedt, B. & Naumann, U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol 101, 365-77 (2011).
16. Eisermann, K., Broderick, C. J., Bazarov, A., Moazam, M. M. & Fraizer, G. C. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer 12, 7 (2013).
17. Anorlu, R. I. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 16, 41-9 (2008).
18. Vici, P. et al. Emerging Biological Treatments for Uterine Cervical Carcinoma. J Cancer 5, 86-97 (2014).
19. Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F. & Barni, S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 133, 117-23 (2014).
20. Agoni, L. et al. Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo. Int J Radiat Oncol Biol Phys 88, 1180-7 (2014).
21. Korsmeyer, S. J. et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7, 1166-73 (2000).
22. Garnett, T. O., Filippova, M. & Duerksen-Hughes, P. J. Bid is cleaved upstream of caspase-8 activation during TRAIL-mediated apoptosis in human osteosarcoma cells. Apoptosis 12, 1299-315 (2007).
23. Sleiman, S. F. et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 31, 6858-70 (2011).
24. Malek, A. et al. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7, e35130 (2012).
25. Wang, L. et al. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33, 161-7 (2008).
26. Haie-Meder, C., Morice, P. & Castiglione, M. Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2, ii17-8 (2008).
27. Nogueira-Rodrigues, A. et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 120, 1187-93 (2014).
28. Leath, C. A., 3rd & Straughn, J. M., Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129, 251-7 (2013).
29. Choi, E. S. et al. Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells. J Clin Biochem Nutr 53, 89-93 (2013).
30. Shin, J. A., Jung, J. Y., Ryu, M. H., Safe, S. & Cho, S. D. Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization. Mol Pharmacol 83, 33-41 (2013).
31. Duverger, V. et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer 90, 2025-31 (2004).
32. Koutsodontis, G. & Kardassis, D. Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene 23, 9190-200 (2004).
33. Barcelo, F. et al. Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res 35, 2215-26 (2007).
34. Wierstra, I. Sp1: emerging roles--beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 372, 1-13 (2008).
35. Wang, Y. T. et al. Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol 380, 869-85 (2008).
36. Lecker, S. H., Goldberg, A. L. & Mitch, W. E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17, 1807-19 (2006).
37. Cheng, H. T. & Hung, W. C. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. Oncol Rep 29, 1238-44 (2013).
38. Previdi, S. et al. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 118, 182-8 (2010).
39. French, L. E. & Tschopp, J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 10, 117-23 (2003).
40. Chinnaiyan, A. M. et al. FADD/MORT1 is a common mediator of CD95 (Fas/ APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 271, 4961-5 (1996).
41. Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-90 (1998).